Try as we might, we can’t cover all the biotech news out there! Here’s a roundup of news that didn’t make the cut this week.
- Bayer’s ADC for mesothelioma failed in Phase II, collaterally denting the stocks of its partners MorphoSys and ImmunoGen
- Themis has kicked off a Phase II study of its Chikungunya vaccine in Puerto Rico, where the disease is endemic
- Do presubmission meetings with the EMA open the door for drugmakers to influence MAA decisions? The EU is investigating.
- Emma Walmsley, GSK’s CEO, is making big moves to overhaul the pharma’s pipeline
Images from Brian Lasenby, Nirun Thuwasin, Marco Diaz Segura, Oleksii G, Janossy Gergely, Vladimir Wrangel / shutterstock.com
Support good journalism, subscribe to Labiotech Insider
If you liked this post and want to read more good journalism, support us by joining Labiotech Insider. Our Insider membership gives you access to exclusive content and other advantages.